ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GDR Genedrive Plc

5.50
-0.625 (-10.20%)
Last Updated: 10:30:10
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.625 -10.20% 5.50 5.25 5.75 6.25 5.125 6.25 2,210,179 10:30:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0447 -1.20 6.18M

Genedrive PLC Notice of Interim Results (3252A)

24/03/2017 7:01am

UK Regulatory


Genedrive (LSE:GDR)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Genedrive Charts.

TIDMGDR

RNS Number : 3252A

Genedrive PLC

24 March 2017

RNS

For release: 24 March 2017

genedrive plc ("genedrive" or the "Company")

Notice of Interim Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ended 31 December 2016 on Thursday, 30 March 2017.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO

+44 (0)161 989 0245

Matthew Fowler: Finance Director

Peel Hunt LLP

James Steel

+44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com

Notes to Editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) platform and MTB/RIF test have been launched in India and a Genedrive(R) HCV test has been successfully assessed by the Institut Pasteur, Paris.

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORPGUMGWUPMGGW

(END) Dow Jones Newswires

March 24, 2017 03:01 ET (07:01 GMT)

1 Year Genedrive Chart

1 Year Genedrive Chart

1 Month Genedrive Chart

1 Month Genedrive Chart

Your Recent History

Delayed Upgrade Clock